Aanal Bhatt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aanal Bhatt has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Ammar Arsiwala
Ginkgo Bioworks, Inc, MA, USA
3 shared publications - Lucia Grippo
Ginkgo Bioworks, Inc, MA, USA
3 shared publications - Peter M. Tessier
Department of Chemical Engineering, University of Michigan
3 shared publications Rich Cohen
Ginkgo Bioworks, Inc, MA, USA
3 shared publications- Xiang Ao
Ginkgo Bioworks, Inc, MA, USA
3 shared publications - Adam Rosenbaum
Ginkgo Bioworks Inc
2 shared publications
Latest Publications
- Open Access
Decoding Bispecific Antibody Developability: Design Rules and Predictive Models from a 160-Member Library
Bispecific antibodies deliver functional outcomes that monospecific antibodies cannot, yet emergent self-association, polyreactivity, and aggregation often degrade their developability relative to their parental arms. Whether bispecific developability inherits from the parents or is driven by the format has not been tested at scale. We characterized 160 bispecific antibodies and their 65 parental arms on a uniform knobs-into-holes CrossMab IgG1 scaffold across 10 assays on the PROPHET-Ab high-throughput platform. Bispecific developability separates into three classes of inheritance. Hydrophobicity and surface charge inherit cleanly from the parents (Spearman ρ ≈ 0.85 to 0.95), so parental-level screening predicts bispecific fate. Self-association and polyreactivity inherit partially (ρ ≈ 0.60 to 0.88), with mechanistically interpretable emergent outliers driven in part by Fv-Fv charge complementarity and a parental biophysical ceiling on the hydrophobicity (HIC) by surface-charge (HAC) plane. Thermostability is poorly predicted from parental antibodies (ρ < 0.4), so it requires bispecific-level testing. The class framework yields actionable selection rules: triage hydrophobicity and charge at the parental level, avoid pairing two high-HIC x high-HAC arms, pair opposite-sign Fv charges to suppress self-association but re-validate at the formulation buffer, and measure thermostability on the bispecific itself. This work charts a tractable path from monospecific sequence to bispecific developability prediction. Significance: Bispecific antibodies are a fast-growing therapeutic class, yet the rational design of well-behaving bispecific antibodies from validated monospecific antibody building blocks remains challenging. A key bottleneck is the lack of comprehensive, high-quality public datasets linking parental antibody developability properties to corresponding bispecific antibody developability properties. We address this gap by releasing a dataset comprising 160 bispecific antibodies and the 65 parental monospecific antibodies profiled in 10 developability assays. The data show that bispecific antibody developability is complex. Some properties are easily predictable from the parents, whereas others emerge in the bispecific format or from the bispecific format itself. The factors that govern each property can be identified empirically and used to make practical selection decisions. The mechanistic explanations and predictive models reported here establish a compact set of actionable rules. Together, they define a framework for using computational pipelines to convert monospecific antibodies into bispecific antibodies with drug-like developability properties, enabling faster and more effective generation of high-quality bispecific antibodies for diverse therapeutic applications.
Open AccessDecoding Bispecific Antibody Developability: Design Rules and Predictive Models from a 160-Member Library
Bispecific antibodies deliver functional outcomes that monospecific antibodies cannot, yet emergent self-association, polyreactivity, and aggregation often degrade their developability relative to their parental arms. Whether bispecific developability inherits from the parents or is driven by the format has not been tested at scale. We characterized 160 bispecific antibodies and their 65 parental arms on a uniform knobs-into-holes CrossMab IgG1 scaffold across 10 assays on the PROPHET-Ab high-throughput platform. Bispecific developability separates into three classes of inheritance. Hydrophobicity and surface charge inherit cleanly from the parents (Spearman ρ ≈ 0.85 to 0.95), so parental-level screening predicts bispecific fate. Self-association and polyreactivity inherit partially (ρ ≈ 0.60 to 0.88), with mechanistically interpretable emergent outliers driven in part by Fv-Fv charge complementarity and a parental biophysical ceiling on the hydrophobicity (HIC) by surface-charge (HAC) plane. Thermostability is poorly predicted from parental antibodies (ρ < 0.4), so it requires bispecific-level testing. The class framework yields actionable selection rules: triage hydrophobicity and charge at the parental level, avoid pairing two high-HIC x high-HAC arms, pair opposite-sign Fv charges to suppress self-association but re-validate at the formulation buffer, and measure thermostability on the bispecific itself. This work charts a tractable path from monospecific sequence to bispecific developability prediction. Significance: Bispecific antibodies are a fast-growing therapeutic class, yet the rational design of well-behaving bispecific antibodies from validated monospecific antibody building blocks remains challenging. A key bottleneck is the lack of comprehensive, high-quality public datasets linking parental antibody developability properties to corresponding bispecific antibody developability properties. We address this gap by releasing a dataset comprising 160 bispecific antibodies and the 65 parental monospecific antibodies profiled in 10 developability assays. The data show that bispecific antibody developability is complex. Some properties are easily predictable from the parents, whereas others emerge in the bispecific format or from the bispecific format itself. The factors that govern each property can be identified empirically and used to make practical selection decisions. The mechanistic explanations and predictive models reported here establish a compact set of actionable rules. Together, they define a framework for using computational pipelines to convert monospecific antibodies into bispecific antibodies with drug-like developability properties, enabling faster and more effective generation of high-quality bispecific antibodies for diverse therapeutic applications.
- Top Cited PapersOpen Access
- 22 February 2026
- Published by Taylor & Francis in mAbs
- Vol. 18 (1) , 2634216
2025 Ginkgo Datapoints Antibody Developability Competition outcomes: limited model performance and a call for data standardization
Monoclonal antibodies (mAbs) are among the most successful therapeutic modalities, with over 200 marketed products and nearly 1400 candidates in clinical development.1 While high-affinity binding r...
- 22 February 2026
- Published by Taylor & Francis in mAbs
- Vol. 18 (1) , 2634216
Top Cited PapersOpen Access2025 Ginkgo Datapoints Antibody Developability Competition outcomes: limited model performance and a call for data standardization
Monoclonal antibodies (mAbs) are among the most successful therapeutic modalities, with over 200 marketed products and nearly 1400 candidates in clinical development.1 While high-affinity binding r...
- Open Access
- 2 December 2025
- Published by Taylor & Francis in mAbs
- Vol. 17 (1) , 2593055
A high-throughput platform for biophysical antibody developability assessment to enable AI/ML model training
Antibodies must bind their targets with high affinity and specificity to achieve useful therapeutic activity. They must also possess suitable developability properties (e.g. thermostability, solubility, viscosity, polyreactivity) to ensure favorable manufacturing, formulation, and in vivo performance. Both binding and developability properties are inherent to a given antibody amino acid sequence. Identification or selection of antibodies possessing suitable-binding characteristics is now routine, and de novo computational design models, trained on extensive complementarity-determining region sequence and structural data, are rapidly improving. Developability properties, however, remain difficult to predict largely due to insufficient training data, with empirical testing being heavily used to avoid challenges in late-stage antibody development. To fill this gap, we built a high-throughput antibody developability assay platform designed to generate the large datasets needed to train improved machine learning (ML) models. We optimized and automated known developability assays, and developed a robust integrated data analytics pipeline. Here, we report data on 246 antibodies - representing 106 approved, 135 clinical-stage, and 5 preregistration/withdrawn molecules - across a panel of 10 developability assays, in a "tidy data" format suitable for AI/ML modeling. We used these data to develop an XGBoost ML model that better predicts similarity to approved antibodies compared to conventional use of developability warning thresholds. Additionally, we confirm that preliminary predictive models do improve with more training data. Our high-throughput PROPHET-Ab platform enables data generation at the scale needed to develop improved ML models to predict antibody developability.
- 2 December 2025
- Published by Taylor & Francis in mAbs
- Vol. 17 (1) , 2593055
Open AccessA high-throughput platform for biophysical antibody developability assessment to enable AI/ML model training
Antibodies must bind their targets with high affinity and specificity to achieve useful therapeutic activity. They must also possess suitable developability properties (e.g. thermostability, solubility, viscosity, polyreactivity) to ensure favorable manufacturing, formulation, and in vivo performance. Both binding and developability properties are inherent to a given antibody amino acid sequence. Identification or selection of antibodies possessing suitable-binding characteristics is now routine, and de novo computational design models, trained on extensive complementarity-determining region sequence and structural data, are rapidly improving. Developability properties, however, remain difficult to predict largely due to insufficient training data, with empirical testing being heavily used to avoid challenges in late-stage antibody development. To fill this gap, we built a high-throughput antibody developability assay platform designed to generate the large datasets needed to train improved machine learning (ML) models. We optimized and automated known developability assays, and developed a robust integrated data analytics pipeline. Here, we report data on 246 antibodies - representing 106 approved, 135 clinical-stage, and 5 preregistration/withdrawn molecules - across a panel of 10 developability assays, in a "tidy data" format suitable for AI/ML modeling. We used these data to develop an XGBoost ML model that better predicts similarity to approved antibodies compared to conventional use of developability warning thresholds. Additionally, we confirm that preliminary predictive models do improve with more training data. Our high-throughput PROPHET-Ab platform enables data generation at the scale needed to develop improved ML models to predict antibody developability.
- Open Access
- 8 March 2022
- Published by Elsevier in Cell Reports
- Vol. 38 (10) , 110473
Deletion of STAT3 from Foxd1 cell population protects mice from kidney fibrosis by inhibiting pericytes trans-differentiation and migration
- 8 March 2022
- Published by Elsevier in Cell Reports
- Vol. 38 (10) , 110473
Open AccessDeletion of STAT3 from Foxd1 cell population protects mice from kidney fibrosis by inhibiting pericytes trans-differentiation and migration